Eli Lilly’s drug tirzepatide, sold under the names Mounjaro for diabetes and Zepbound for weight loss, improved symptoms in heart failure patients with obesity, the company said Thursday.

Tirzepatide, currently marketed by Eli Lilly (NYSE:LLY) as Mounjaro and Zepbound for diabetes and weight loss, respectively, reduced the risk of worsening heart failure events by 38% in adults ...

Tirzepatide reduced cardiovascular death or heart failure worsening by 38% in patients ... ejection fraction (HFpEF), it sharply cuts the risk of dying from a cardiovascular (CV) event or seeing ...

Eli Lilly's tirzepatide has been shown to significantly cut cardiovascular risks in patients with obesity and a form of heart failure with few treatment options, in another big win for the GLP-1 ...

INDIANAPOLIS, Nov. 16, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from the SUMMIT Phase 3 trial showing tirzepatide significantly reduced the risk of ...

Sold as Zepbound and Mounjaro, the medication reduced the likelihood of hospitalization and death by nearly 40 percent in a new study. Tirzepatide lowered the risk of heart failure–related ...

Data from the SUMMIT clinical trial demonstrated that tirzepatide lowered the risk of negative heart failure outcomes and enhanced symptoms and physical limitations when tested with three different ...

Treatment with tirzepatide reduced the risk of time-to-first occurrence of heart failure outcomes by 38% compared with placebo. Treatment with tirzepatide was associated with a reduction in the ...

The study found participants in the tirzepatide group had a reduced combined risk of cardiovascular death and worsening heart failure events compared to the participants in the placebo group.